Overview of Al for Medical and Public Health Preparedness and Response





November 8th, 2023

Samuel V. Scarpino, PhD

Director of AI + Life Sciences, Institute for Experiential AI.

Professor of the Practice, Health Sciences & Computer Sciences

Northeastern University

External Professor, Santa Fe Institute

s.scarpino@northeastern.edu

Northeastern University is the World Leader in Experiential Learning & Enterprise Collaboration

#53

Overall Ranking (out of 443 U.S. Universities)

#1

in Experiential Coops and Internship Programs* #8

Most
Innovative
Universities*

\$230.7M+

External Research Funding

\$1.5B+


Educational and Research
Endowment

3,000+

Corporate Partners Across NU Worldwide Experiential Network 9

Interdisciplinary
Institutes

Our Global University System




Strategic Digitization is one of the grand challenges facing us today

What Has Digital Transformation Looked Like in Health? A tale of two illustrative journeys; Radiology vs. Pathology

- Slower digitization and digitalization than other fields
- Great advances in device tech from diagnostics, surgical to imaging
- Interesting examples of inconsistent adoption of digital & Al Some sample examples of uses of Al:

	Routine Medical Diagnostics	Cell Imaging	The Omics
✓ ×	Radiology: digitized and a lot of automation	Great advances in technology down to subsingle-cell	Great advances in Genomics, Proteomics, and Transcriptomics
	Pathology: still in the land of analog and little Al processing	Very few large-scale uses	Very little work on combining omics and integrating metabolomics








What About Electronic Medical Records?

- Mandated digital coding and medical notes
- Failure to standardize the Data
- No two EHR's look the same...
- Very fragmented space, and even the largest EHR systems do not inter-operate
- No real incentives to share data


This results in great difficulty to leverage AI/ML and automated analytics to help leverage the wealth of data

The average hospital has 16 disparate EMR vendors in use at affiliated practices Most hospitals have 10 EHR systems, and only 2% are down to only two EHR systems!





1. Poised to accelerate.




Source: KPMG 2021 Thriving in an Al World survey across 7 industries



© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.



- 1. Poised to accelerate.
- 2. Concerns about the pace of adoption.




Percent of business leaders who think the pace of Al adoption in their sector is too fast.

Source: KPMG 2021 Thriving in an Al World survey across 7 indust



© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independe member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved.

- 1. Poised to accelerate.
- 2. Concerns about the pace of adoption.
- 3. Proliferation of tools and algorithms.





- 1. Poised to accelerate.
- 2. Concerns about the pace of adoption.
- 3. Proliferation of tools and algorithms.
- 4. Concerns about cybersecurity, ethical use, and bias.

RESEARCH Open Access

Risk of bias of prognostic models developed using machine learning: a systematic review in oncology



Paula Dhiman^{1,2*}, Jie Ma¹, Constanza L. Andaur Navarro^{3,4}, Benjamin Speich^{1,5}, Garrett Bullock⁶, Johanna A. A. Damen^{3,4}, Lotty Hooft^{3,4}, Shona Kirtley¹, Richard D. Riley⁷, Ben Van Calster^{8,9,10}, Karel G. M. Moons^{3,4} and Gary S. Collins^{1,2}

- 1. Poised to accelerate.
- 2. Concerns about the pace of adoption.
- 3. Proliferation of tools and algorithms.
- 4. Concerns about cybersecurity, ethical use, and bias.
- 5. Investors are less experienced and decisions are complex.

Around 85% of biotech investors have been working in the field for less than a decade, according to an Omega Funds tally

STAT+

VC deals and valuations begin falling apart amid biotech's stock shock



Reprints

- 1. Poised to accelerate.
- 2. Concerns about the pace of adoption.
- 3. Proliferation of tools and algorithms.
- 4. Concerns about cybersecurity, ethical use, and bias.
- 5. Investors are less experienced and decisions are complex.


And on top of all that, biotech is just so technically complex. Investing legend Peter Lynch advised everyone to invest in a well-researched subset of "what you know." That pretty much nixes biotech for the vast majority of investors, even professionals.

Biotech's Dulcius Ex Asperis: The Way Through This Downturn





- 1. Poised to accelerate.
- 2. Concerns about the pace of adoption.
- 3. Proliferation of tools and algorithms.
- 4. Concerns about cybersecurity, ethical use, and bias.
- 5. Investors are less experienced and decisions are complex.
- 6. Enthusiasm for AI's ability to improve public health



KPMG

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee, All rights reserved.



Biggest opportunities for AI in healthcare/public health

Drug discovery

- Identifying novel biomolecules.
- Toxicity prediction.
- Smart trial design/enrollment.
- Drug repurposing and novel combinations.

Process Optimization

- Bioinformatic pipeline development.
- Pathogen risk stratification.
- Literature review and synthesis.
- Form completion/reporting.

Diagnostics

- Integration of multi-omics data to improve diagnostics.
- Partition of diseases based on biomarkers.
- Earlier detection of disease and progression.

Misinformation

- Identification of mis/disinformation.
- Chatbots for public health/healthcare messaging.
- Reliable search for real-time, accurate information on outbreaks/risks.

Early warning systems

- AI applied to environmental (e..g, wastewater) surveillance.
- Integration of mobility data with healthcare-facility-level information.
- Federated learning across jurisdictions.

Situational Awareness

- Automated data integration.
- Enhanced forecasting capabilities.
- Multi-pathogen wastewater surveillance.
- Screening for AMRs and other resistance markers.

How do we get started?

- Build a community around standards. E.g., Build ontologies/schema, common data models, APIs, etc..
- Leverage ML/AI (human-in-the-loop) for integrating data.
- Federated data models, including computing infrastructure.
- Legal and ethical frameworks.
- Multi-stakeholder engagement around technology/data needs. E.g., Ambiant intelligence, cloud<->edge computing, etc.
- Training for the next generation of health data researchers and policy-makers.
 - E.g., NIH Fogarty RAPIDD 2.0? Program targeted at policy-makers?

Learn more about AI at Northeastern University!

Samuel V. Scarpino, PhD

s.scarpino@northeastern.edu





